Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: FibroGen Q2 Earnings

  FibroGen (NASDAQ:FGEN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

FibroGen (NASDAQ:FGEN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

FibroGen beat estimated earnings by 17.02%, reporting an EPS of $-0.78 versus an estimate of $-0.94.

Revenue was up $5.44 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.15 which was followed by a 25.82% increase in the share price the next day.

 

To track all earnings releases for FibroGen visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cae Announces Re-Baselining Of Its Defense Business; Defense Records $568M Goodwill Impairment, $90.3M Unfavourable Contract Adjustments, And $35.7M Impairment Of Related Intangible Assets; Appoints Of Nick Leontidis As COO

By Benzinga Newsdesk
May 21, 4:33 PM
CAE Inc. (CAE or the Company) today announced a re-baselining of its Defense business along with Defense impairments and unfavourable contract adjustments related to eight previously identified fixed-price legacy

CAE